Study Study design Total no. of patients No. of patients No. of patients Age (Mean±SD) Age (Mean±SD) Male sex No. (%) Male sex No. (%) BMI kg/m2 (Mean±SD) BMI kg/m2 (Mean±SD) HBA1C% (Mean±SD) HBA1C% (Mean±SD) Systolic blood pressure (Mean ±SD) Systolic blood pressure (Mean ±SD) Diastolic blood pressure (Mean ±SD) Diastolic blood pressure (Mean ±SD) Serum potassium (Mean ±SD) Serum potassium (Mean ±SD)
Finerenone Placebo Finerenone Placebo Finerenone Placebo Finerenone Placebo Finerenone Placebo Finerenone Placebo Finerenone Placebo Finerenone Placebo
Bakris (2015)[13] RCT 821 727 94 63.9± 9.2 63.2±8.6 570 (78.4) 69 (73.4) 31.7± 5.5 32.4± 5.2 7.58± 1.2 7.6± 1.3 137.9±14.3 139.9±14.3 77± 9.7 78.2± 9.7 4.3± 0.3 4.3± 0.4
Katayama (2017)[17] RCT 96 84 12 62.4± 9.9 66.7± 9 67 (79.7) 10 (83.3) 27± 74.1 26.6± 3.2 7.21± 0.9 7.28± 0.7 137.2± 14.8 135.7± 16.9 77.18± 10.8 69.2± 11.6 4.18± 0.2 4.21± 0.1
Bakris (2020)[14] RCT 5674 2833 2841 65.4± 8.9 65.7±9.2 1953 (68.9) 2030 (71.5) 31.1± 6.0 31.1± 6.0 7.7± 1.3 7.7± 1.4 138.1±14.3 138.0± 14.4 75.8 ± 9.7 75.8 ± 9.7 4.37± 0.4 4.38± 0.4
Bertram (2021)[10] RCT 7352 3686 3666 64.1± 9.7 64.1±10 2528 (68.6) 2577 (70.3) 31.5± 6.0 31.4± 5.9 7.7± 1.4 7.7± 1.4 135.8±14.0 135.7± 14.1 76.8 ± 9.5 76.8 ± 9.6 4.33± 0.4 4.33± 0.4
Gerasimos (2021)[15] RCT 5674 2833 2841 65.5± 8.8 65.8±9 1953 (68.9) 2030 (71.4) 31.1± 6 31.1± 6 7.7± 1.3 7.7± 1.4 138± 14.3 138± 14.4 75.8± 9.7 75.8± 9.6 4.37± 0.4 4.37± 0.4
Agarwal (2022)[5] RCT 13026 6519 6507 64.7± 9.4 64.8 ± 9.7 4481 (68.7) 4607 (70.8) N/A N/A 7.7± 1.4 7.7 ± 1.4 136.8 ± 14.2 136.7± 14.3 76.3 ± 9.6 76.4 ± 9.6 4.35 ± 0.4 4.35 ± 0.4
Gerasimos (2022)[16] RCT 7352 3686 3666 64.4± 9.34 65.1± 9.41 2528 (68.5) 2577 (70.2) 32.28± 6.2 31.84± 5.9 7.8± 1.4 7.79± 1.3 135.7± 13.7 135.3± 13.9 77.12± 9.6 76.41± 9.9 4.37± 0.3 4.35± 0.4